Holen Sie sich die Stockscreener-App
3.5155
0.14%
-0.0155
Rezolute Inc Aktie (RZLT) Neueste Nachrichten
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - marketscreener.com
Analysis Recap: Will Rezolute Inc benefit from rate cutsJuly 2025 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options - Intellectia AI
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - PR Newswire
RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc.RZLT - PR Newswire
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.
Trading Recap: Is Rezolute Inc a top pick in the sectorPortfolio Gains Summary & Safe Swing Trade Setups - baoquankhu1.vn
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The Malaysian Reserve
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - Sahm
FMR LLC Significantly Reduces Holdings in Rezolute Inc. - GuruFocus
Entry Recap: Is Rezolute Inc a top pick in the sectorMarket Activity Summary & Precise Swing Trade Alerts - baoquankhu1.vn
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Chartmill
RZLT ALERT: Levi & Korsinsky Investigates Rezolute, Inc. for Possible Securities Fraud Violations - marketscreener.com
RZLT Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - marketscreener.com
Rezolute Downgrade Brings Investor Caution Amid Study Challenges - StocksToTrade
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - MarketScreener
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Is Rezolute Inc. stock positioned well for digital economyJuly 2025 Big Picture & Daily Volume Surge Signals - ulpravda.ru
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans - TipRanks
Did You Suffer Losses in Rezolute, Inc. (RZLT)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Does Rezolute Inc. stock trade at a discount to peersAnalyst Upgrade & Long-Term Safe Return Strategies - ulpravda.ru
Will Rezolute Inc. (6HV1) stock test record highs in 2025Market Activity Report & Fast Entry Momentum Alerts - ulpravda.ru
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Bluefield Daily Telegraph
Rezolute (RZLT): Wedbush Analyst Raises Price Target to $2.00 | - GuruFocus
Why analysts upgrade Rezolute Inc. stockJuly 2025 Macro Moves & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Rezolute (NASDAQ:RZLT) Given Buy Rating at BTIG Research - MarketBeat
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target By Investing.com - Investing.com Canada
Wedbush Doubles Price Target on Rezolute to $2 From $1, Keeps Neutral Rating - marketscreener.com
BTIG Reiterates Buy Rating for Rezolute (RZLT) with $5 Target Pr - GuruFocus
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism - StreetInsider
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target - Investing.com
Rezolute Hopes To Find A Way Forward In Congenital HI After Phase III Miss - Citeline News & Insights
Rezolute (RZLT) Shows Promising Results in Hypoglycemia Treatmen - GuruFocus
Can Rezolute's SunRIZE Study, Tumor HI Data Redefine Treatment For Hyperinsulinism? - Nasdaq
Rezolute (RZLT) Analyzes Phase 3 sunRIZE Study Outcomes - GuruFocus
Rezolute shares mixed results from Phase 3 trial for rare disease therapy - Investing.com Nigeria
Rezolute shares mixed results from Phase 3 trial for rare disease therapy By Investing.com - Investing.com South Africa
Rezolute rises as drug shows promise for rare low blood sugar disorders - TradingView — Track All Markets
Rezolute, Inc. Shares Findings on Ersodetug's Efficacy for Congenital and Tumor Hyperinsulinism, Plans FDA Meeting to Discuss Path Forward - Quiver Quantitative
Rezolute, Inc. Provides Insights from sunRIZE Study and EAP - TradingView — Track All Markets
Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. ... - Bluefield Daily Telegraph
1.31%
3.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):